Deep brain stimulation of the subthalamic nucleus: All that glitters isn't gold?

Salvatore Galati, Alessandro Stefani

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

With the silver anniversary of deep brain stimulation (DBS) behind us, this would seem to be a good juncture to consider its successes and unanswered questions. Bilateral subthalamic nucleus (STN) stimulation has changed the clinical perspective of several thousand Parkinson's disease (PD) patients worldwide. A recent reappraisal animates the field with strong arguments in favor of an anticipation of the stereotactic approach in patients with as little as 5 to 6 years of disease history if they manifest motor complications. From what was once a no-choice option, STN-DBS is now becoming more and more attractive to neurologists dealing with movement disorders. Despite the development of new pharmacological treatment and renewed rehabilitation programs able to modify the severity of drug-related complications, a resurgence of stimulation therapy reminiscent of an old era of medicine with an attendant blinkered mindset has emerged. Yet, the DBS-mediated effects are modest on critical aspects such as gait impairment and extremely variable depending on the clinical phenotype and individual clinical profile. Hence, the indication for DBS should become more, and not less, individually tailored. Those physicians considering deep brain stimulation (DBS) as a therapeutic option need to evaluate results beyond short-term quality of life, giving the correct weight to the direct and indirect costs over the longer term as well as to life prognosis. Unequivocal recourse to early-stimulation surgery necessitates investigations not limited to a mere comparative assessment versus drug-mediated benefits, but instead showing evidence of a clear degree of disease-modifying effect or a rescue of basal ganglia plasticity.

Original languageEnglish
Pages (from-to)632-637
Number of pages6
JournalMovement Disorders
Volume30
Issue number5
DOIs
Publication statusPublished - Apr 15 2015

Fingerprint

Subthalamic Nucleus
Deep Brain Stimulation
Gold
Movement Disorders
Anniversaries and Special Events
Basal Ganglia
Gait
Silver
Pharmaceutical Preparations
Parkinson Disease
Therapeutics
Rehabilitation
Quality of Life
Medicine
Pharmacology
Physicians
Phenotype
Weights and Measures
Costs and Cost Analysis

Keywords

  • Parkinson's disease
  • Stereotactic neurosurgery

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Deep brain stimulation of the subthalamic nucleus : All that glitters isn't gold? / Galati, Salvatore; Stefani, Alessandro.

In: Movement Disorders, Vol. 30, No. 5, 15.04.2015, p. 632-637.

Research output: Contribution to journalArticle

Galati, Salvatore ; Stefani, Alessandro. / Deep brain stimulation of the subthalamic nucleus : All that glitters isn't gold?. In: Movement Disorders. 2015 ; Vol. 30, No. 5. pp. 632-637.
@article{2b27b8a4ffc6473db3e1247e99076136,
title = "Deep brain stimulation of the subthalamic nucleus: All that glitters isn't gold?",
abstract = "With the silver anniversary of deep brain stimulation (DBS) behind us, this would seem to be a good juncture to consider its successes and unanswered questions. Bilateral subthalamic nucleus (STN) stimulation has changed the clinical perspective of several thousand Parkinson's disease (PD) patients worldwide. A recent reappraisal animates the field with strong arguments in favor of an anticipation of the stereotactic approach in patients with as little as 5 to 6 years of disease history if they manifest motor complications. From what was once a no-choice option, STN-DBS is now becoming more and more attractive to neurologists dealing with movement disorders. Despite the development of new pharmacological treatment and renewed rehabilitation programs able to modify the severity of drug-related complications, a resurgence of stimulation therapy reminiscent of an old era of medicine with an attendant blinkered mindset has emerged. Yet, the DBS-mediated effects are modest on critical aspects such as gait impairment and extremely variable depending on the clinical phenotype and individual clinical profile. Hence, the indication for DBS should become more, and not less, individually tailored. Those physicians considering deep brain stimulation (DBS) as a therapeutic option need to evaluate results beyond short-term quality of life, giving the correct weight to the direct and indirect costs over the longer term as well as to life prognosis. Unequivocal recourse to early-stimulation surgery necessitates investigations not limited to a mere comparative assessment versus drug-mediated benefits, but instead showing evidence of a clear degree of disease-modifying effect or a rescue of basal ganglia plasticity.",
keywords = "Parkinson's disease, Stereotactic neurosurgery",
author = "Salvatore Galati and Alessandro Stefani",
year = "2015",
month = "4",
day = "15",
doi = "10.1002/mds.26149",
language = "English",
volume = "30",
pages = "632--637",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Deep brain stimulation of the subthalamic nucleus

T2 - All that glitters isn't gold?

AU - Galati, Salvatore

AU - Stefani, Alessandro

PY - 2015/4/15

Y1 - 2015/4/15

N2 - With the silver anniversary of deep brain stimulation (DBS) behind us, this would seem to be a good juncture to consider its successes and unanswered questions. Bilateral subthalamic nucleus (STN) stimulation has changed the clinical perspective of several thousand Parkinson's disease (PD) patients worldwide. A recent reappraisal animates the field with strong arguments in favor of an anticipation of the stereotactic approach in patients with as little as 5 to 6 years of disease history if they manifest motor complications. From what was once a no-choice option, STN-DBS is now becoming more and more attractive to neurologists dealing with movement disorders. Despite the development of new pharmacological treatment and renewed rehabilitation programs able to modify the severity of drug-related complications, a resurgence of stimulation therapy reminiscent of an old era of medicine with an attendant blinkered mindset has emerged. Yet, the DBS-mediated effects are modest on critical aspects such as gait impairment and extremely variable depending on the clinical phenotype and individual clinical profile. Hence, the indication for DBS should become more, and not less, individually tailored. Those physicians considering deep brain stimulation (DBS) as a therapeutic option need to evaluate results beyond short-term quality of life, giving the correct weight to the direct and indirect costs over the longer term as well as to life prognosis. Unequivocal recourse to early-stimulation surgery necessitates investigations not limited to a mere comparative assessment versus drug-mediated benefits, but instead showing evidence of a clear degree of disease-modifying effect or a rescue of basal ganglia plasticity.

AB - With the silver anniversary of deep brain stimulation (DBS) behind us, this would seem to be a good juncture to consider its successes and unanswered questions. Bilateral subthalamic nucleus (STN) stimulation has changed the clinical perspective of several thousand Parkinson's disease (PD) patients worldwide. A recent reappraisal animates the field with strong arguments in favor of an anticipation of the stereotactic approach in patients with as little as 5 to 6 years of disease history if they manifest motor complications. From what was once a no-choice option, STN-DBS is now becoming more and more attractive to neurologists dealing with movement disorders. Despite the development of new pharmacological treatment and renewed rehabilitation programs able to modify the severity of drug-related complications, a resurgence of stimulation therapy reminiscent of an old era of medicine with an attendant blinkered mindset has emerged. Yet, the DBS-mediated effects are modest on critical aspects such as gait impairment and extremely variable depending on the clinical phenotype and individual clinical profile. Hence, the indication for DBS should become more, and not less, individually tailored. Those physicians considering deep brain stimulation (DBS) as a therapeutic option need to evaluate results beyond short-term quality of life, giving the correct weight to the direct and indirect costs over the longer term as well as to life prognosis. Unequivocal recourse to early-stimulation surgery necessitates investigations not limited to a mere comparative assessment versus drug-mediated benefits, but instead showing evidence of a clear degree of disease-modifying effect or a rescue of basal ganglia plasticity.

KW - Parkinson's disease

KW - Stereotactic neurosurgery

UR - http://www.scopus.com/inward/record.url?scp=84927067051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927067051&partnerID=8YFLogxK

U2 - 10.1002/mds.26149

DO - 10.1002/mds.26149

M3 - Article

C2 - 25649375

AN - SCOPUS:84927067051

VL - 30

SP - 632

EP - 637

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 5

ER -